Jump to main content
Jump to site search

Issue 14, 2013
Previous Article Next Article

Modifying mesoporous silica nanoparticles to avoid the metabolic deactivation of 6-mercaptopurine and methotrexate in combinatorial chemotherapy

Author affiliations

Abstract

Mesoporous silica nanoparticles with amino and thiol groups (MSNSN) were prepared and covalently modified with methotrexate and 6-mercaptopurine to form 6-MP–MSNSN–MTX. In the presence of DTT, 6-MP–MSNSN–MTX gradually releases 6-MP. In rat plasma, 6-MP–MSNSN–MTX effectively inhibits the metabolic deactivation of 6-MP and MTX. 6-MP–MSNSN–MTX could be an agent for long-acting chemotherapy.

Graphical abstract: Modifying mesoporous silica nanoparticles to avoid the metabolic deactivation of 6-mercaptopurine and methotrexate in combinatorial chemotherapy

Back to tab navigation

Supplementary files

Publication details

The article was received on 13 Jan 2013, accepted on 31 Mar 2013 and first published on 03 Apr 2013


Article type: Communication
DOI: 10.1039/C3NR00227F
Citation: Nanoscale, 2013,5, 6249-6253
  •   Request permissions

    Modifying mesoporous silica nanoparticles to avoid the metabolic deactivation of 6-mercaptopurine and methotrexate in combinatorial chemotherapy

    W. Wang, C. Fang, X. Wang, Y. Chen, Y. Wang, W. Feng, C. Yan, M. Zhao and S. Peng, Nanoscale, 2013, 5, 6249
    DOI: 10.1039/C3NR00227F

Search articles by author

Spotlight

Advertisements